路透上海7月13日 - 总部位于波士顿的药物研发公司Insilico Medicine（03696.HK）表示，中国制药企业中国医疗系统（China Medical System， 0867.HK）将就中枢神经系统疾病领域的研发项目，根据里程碑进展支付最高约12亿元人民币（约合1.77亿美元）的款项。
路透上海7月13日 - 总部位于波士顿的药物研发公司Insilico Medicine（03696.HK）表示，中国制药企业中国医疗系统（China Medical System， 0867.HK）将就中枢神经系统疾病领域的研发项目，根据里程碑进展支付最高约12亿元人民币（约合1.77亿美元）的款项。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.